Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.

[1]  Toru Hirano,et al.  Anabolic Effects of Human Biosynthetic Parathyroid Hormone Fragment (1–34), LY333334, on Remodeling and Mechanical Properties of Cortical Bone in Rabbits , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  O. Tørring,et al.  The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). , 1991, Endocrinology.

[3]  D. Burr,et al.  Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis). , 2001, Bone.

[4]  R. Recker,et al.  Treatment of Skeletally Mature Ovariectomized Rhesus Monkeys With PTH(1‐84) for 16 Months Increases Bone Formation and Density and Improves Trabecular Architecture and Biomechanical Properties at the Lumbar Spine , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  D. Burr,et al.  Intermittently Administered Human Parathyroid Hormone(1–34) Treatment Increases Intracortical Bone Turnover and Porosity Without Reducing Bone Strength in the Humerus of Ovariectomized Cynomolgus Monkeys , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  X. Guo,et al.  Trabecular Bone Response to Mechanical and Parathyroid Hormone Stimulation: The Role of Mechanical Microenvironment , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  R. Isaacs,et al.  The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats , 2001, Calcified Tissue International.

[8]  R. Recker,et al.  The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. , 1993, Endocrinology.

[9]  C. Lees,et al.  Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. , 1999, The Journal of clinical endocrinology and metabolism.

[10]  C. Turner,et al.  Decreased Bone Mass and Strength in Ovariectomized Cynomolgus Monkeys (Macaca fascicularis) , 1997, Calcified Tissue International.

[11]  Hui Zhong,et al.  Kinematic and EMG determinants in quadrupedal locomotion of a non-human primate (Rhesus). , 2005, Journal of neurophysiology.

[12]  R. Lindsay,et al.  Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis , 2007, Annals of Internal Medicine.

[13]  E. Glass,et al.  Teriparatide [PTH(1–34)] Strengthens the Proximal Femur of Ovariectomized Nonhuman Primates Despite Increasing Porosity , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  O. Tørring,et al.  Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  C. Turner.  Biomechanics of Bone: Determinants of Skeletal Fragility and Bone Quality , 2002, Osteoporosis International.

[16]  Jiliang Li,et al.  Parathyroid hormone enhances mechanically induced bone formation, possibly involving L-type voltage-sensitive calcium channels. , 2003, Endocrinology.

[17]  G. Dalsky,et al.  Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.

[18]  N. Binkley,et al.  Zoledronate Prevents the Development of Absolute Osteopenia Following Ovariectomy in Adult Rhesus Monkeys , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  M. Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis , 2004 .

[20]  R. Recker,et al.  Daily Treatment of Aged Ovariectomized Rats with Human Parathyroid Hormone (1-84) for 12 Months Reverses Bone Loss and Enhances Trabecular and Cortical Bone Strength , 2006, Calcified Tissue International.

[21]  R. L. Cain,et al.  Six‐Month Daily Administration of Parathyroid Hormone and Parathyroid Hormone—Related Protein Peptides to Adult Ovariectomized Rats Markedly Enhances Bone Mass and Biomechanical Properties: A Comparison of Human Parathyroid Hormone 1–34, Parathyroid Hormone‐Related Protein 1–36, and SDZ‐Parathyroid , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  R. Lindsay,et al.  Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis , 2003 .

[23]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[24]  R. Boyce,et al.  Effects of intermittent hPTH(1–34) alone and in combination with 1,25(OH)2d3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  L. Mosekilde,et al.  Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fascicularis). , 1999, Bone.

[26]  P. Kulkarni,et al.  A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  J. Zanchetta,et al.  Effects of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] on Cortical Bone in Postmenopausal Women With Osteoporosis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  H. Genant,et al.  Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. , 1998, The Journal of clinical investigation.

[29]  C. Turner,et al.  Three-dimensional Modeling of the Effects of Parathyroid Hormone on Bone Distribution in Lumbar Vertebrae of Ovariectomized Cynomolgus Macaques , 2000, Osteoporosis International.

[30]  S. Miller,et al.  Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. , 1998, Bone.

[31]  O. Tørring,et al.  Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. , 1993, Calcified tissue international.

[32]  A. F. Stewart,et al.  Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. , 2003, The Journal of clinical endocrinology and metabolism.

[33]  D. Burr,et al.  The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. , 2001, Advances in experimental medicine and biology.

[34]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Ramon C. Littell,et al.  SAS for Linear Models , 2002 .